Stelleralides D–J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme by Yan, Min et al.
Stelleralides D–J and Anti-HIV Daphnane Diterpenes from 
Stellera chamaejasme
Min Yan†, Yan Lu†, Chin-Ho Chen‡, Yu Zhao§, Kuo-Hsiung Lee§,⊥,*, and Dao-Feng Chen*,†
†Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, 
People’s Republic of China
‡Duke University Medical Center, Box 2926, SORF, Durham, North Carolina 27710, United 
States
§Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of 
North Carolina, Chapel Hill, North Carolina 27599-7568, United States
⊥Chinese Medicine Research and Development Center, China Medical University and Hospital, 
Taichung, Taiwan
Abstract
Bioassay-guided fractionation of a petroleum ether extract of the roots of Stellera chamaejasme 
led to the isolation of seven new (stelleralides D–J, 1–7) and 12 known (8–19) daphnane 
diterpenoids. The structures and relative configurations of 1–7 were established on the basis of 
extensive spectroscopic analysis, including HRESIMS and comprehensive NMR techniques. All 
isolates were evaluated for anti-HIV activity in MT4 cells. All compounds tested, except 2, 
showed anti-HIV activity, and, especially, five 1α-alkyldaphnane diterpenoids (3, 4, 5, 10, and 11) 
exhibited extremely potent anti-HIV activity, with EC50 values of 0.06–1.1 nM and selectivity 
index values of more than 10 000.
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The rapid, worldwide spread of acquired immunodeficiency syndrome (AIDS) has prompted 
an intense research effort to discover compounds that can inhibit effectively the human 
immunodeficiency virus (HIV).1,2 Indeed, highly active antiretroviral therapy (HAART), 
which combines three to four antiretrovirals, can effectively control plasma viremia in many 
patients, although the virus is suppressed rather than truly eradicated.3–5 Thus, a major goal 
of current AIDS therapy continues to be the development of new anti-HIV compounds as 
well as drug regimens for eradication of the AIDS virus.
Stellera chamaejasme L. (Thymelaeaceae), a toxic perennial herb, is distributed prevalently 
in northern and southwestern mainland China and Nepal. Its dried roots, named “Rui-Xiang-
Lang-Du” in traditional Chinese medicine, have long been used for the treatment of 
stubborn skin ulcers, tinea, scabies, tuberculosis, and chronic tracheitis.6 Previous chemical 
investigations on the roots of this plant have led to the isolation of diverse secondary 
metabolites, including highly functionalized daphnane diterpenoids,7–9 tigliane 
diterpenoids,10 lignans,11,12 biflavonoids,13–16 coumarins,17,18 and sesquiterpenoids.11,19 In 
particular, certain daphnane and tigliane diterpenoids have shown extremely potent anti-HIV 
activity at low nanomolar concentrations with relatively low cytotoxicity.7,10 However, 
these compounds are very difficult to synthesize because of their complex structure. 
Accordingly, further analysis of the plant material was conducted to acquire a significant 
quantity of several known, as well as new, anti-HIV diterpenoids from S. chamaejasme.
Consequently, the current research on anti-HIV diterpenoids from S. chamaejasme led to the 
isolation of 19 daphnane diterpenoids, including seven new [stelleralides D–J (1–7)] and 12 
known compounds [stelleralide C (8),7 pimelotide A (9),20 gnidimacrin (10),7 pimelea factor 
P2 (11),7 wikstroelide F (12),7 wikstroelide A (13),21 wikstroelide B (14),22 wikstrotoxin A 
(15),23 huratoxin (16),7 wikstroelide M (17),22 wikstroelide J (18),22 and simplexin (19)7]. 
Herein, are described the isolation and structural elucidation of the new compounds together 
with the anti-HIV activity of all daphnane diterpenoids isolated.
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In a bioassay-guided fractionation of an ethanolic extract (EC50 = 0.42 ± 0.08 μg/mL, 
selectivity index (SI) ≥ 23) of the roots of S. chamaejasme, three solvent fractions 
(petroleum ether, EtOAc, n-BuOH) were obtained. The petroleum ether-soluble fraction 
exhibited promising anti-HIV activity with an EC50 value of 0.06 ± 0.007 μg/mL (SI ≥ 320), 
while the EtOAc-soluble fraction had a higher EC50 value of 1.26 ± 0.19 μg/mL (SI ≥ 15), 
and the n-BuOH-soluble fraction showed no anti-HIV activity. The active fraction was 
separated by repeated column chromatography and preparative HPLC to afford 19 daphnane 
diterpenoids.
Compound 1 was obtained as a colorless oil. Its molecular formula was determined as 
C53H76O12 based on an HRESIMS ion at m/z 927.5235 [M + Na]+ (calcd for C53H76O12Na, 
927.5229), indicating a hydrogen deficiency index (HDI) of 16. The IR spectrum revealed 
the presence of hydroxy (3478 cm−1), carbonyl (1799 and 1718 cm−1), and aromatic groups 
(1648 and 1452 cm−1). The 1H NMR data (Table 1) of 1 indicated two tertiary methyl (δH 
1.73 and 1.79, each 3H, s), one secondary methyl (δH 1.02, 3H, d, J = 6.4 Hz), one primary 
methyl (δH 0.86, 3H, t, J = 8.0 Hz), two oxygenated methylenes (δH 4.09, 4.54, 4.68, and 
4.97), three oxygenated methines (δH 3.44, 4.35, and 4.82), a terminal double bond (δH 5.05 
and 4.94), and five aromatic [δH 7.57 (1H, dd, J = 8.4, 1.2 Hz), 7.46 (2H, dd, J = 8.0, 8.0 
Hz), 8.04 (2H, dd, J = 8.4, 1.2 Hz)] protons. Analysis of the 13C NMR and DEPT spectra of 
1 established the presence of daphnane ketal-lactone skeleton resonances20 including a 
characteristic quaternary carbon resonance at δC 120.4 (C-1′), an acetal carbon resonance at 
δC 112.1 (C-2), a lactone carbonyl carbon resonance at δC 173.9 (C-3), and a methyl carbon 
resonance at δC 19.6 (C-19). Comparison of the 1H and 13C NMR data (Table 1) of 1 with 
those of stelleralide C (8)7 implied the similarity of essential structural signals. Additionally, 
the presence of a fatty acid was suggested [δC 173.8 (C-1‴), 34.1 (C-2‴), 24.7 (C-3‴), 29.0–
29.8 (C-4‴–C-13‴), 31.9 (C-14‴), 22.7 (C-15‴), 14.1 (C-16‴)]. On the basis of the 
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molecular formula, the fatty acid was proposed as palmitic acid. The linkage of palmitic acid 
at C-20 of the diterpenoid skeleton was confirmed by the HMBC correlation between H2-20 
(δH 4.09 and 4.68) and the carbonyl carbon (δC 173.8) of palmitic acid (Figure 1) as well as 
the downfield chemical shift of C-20 from δC 63.0 in 8 to δC 63.9 in 1. Other correlations in 
the HMBC spectrum confirmed the connectivities in this compound.
The relative configuration of 1 was mainly established by comparison of its spectroscopic 
data with those of stelleralide C (8), as well as NOESY results (Figure 1) and molecular 
modeling calculations. The NOESY correlations of H-1/H-19, H-10′/H-1, H-7/H-8, and H-8/
H-14 indicated that these protons are cofacial and β-oriented, while the correlations of H-10/
H-9′, H-9′/H2-18, and H-5/H-10 suggested that these protons are α-oriented. Thus, the 
structure of 1 (stelleralide D) was established as shown.
The molecular formula of compound 2, obtained as a colorless oil, was assigned as 
C55H76O12 according to its HRESIMS (m/z 951.5184 [M + Na]+, calcd for C55H76O12Na, 
951.5229), with an HDI of 18. The IR spectrum indicated the presence of hydroxy (3459 
cm−1), carbonyl (1797 and 1717 cm−1), and aromatic (1455 cm−1) groups. On the basis of 
the 1H and 13C NMR spectra (Table 1), it was evident that 2 has the same daphnane ketal-
lactone skeleton as 1. The key difference between the two compounds was in the lipid motif. 
The signals due to olefin protons (δH 5.32, 5.33, 5.35, and 5.37) were consistent with the 
presence of an unsaturated fatty acid. The lipid group was defined as linoleic acid by 
analysis of the appropriate carbon signals [δC 174.0 (C-1‴), 33.9 (C-2‴), 24.7 (C-3‴), 29.0–
29.8 (C-4‴–C-7‴), 27.1 (C-8‴, C-14‴), 127.9 (C-9‴), 130.2 (C-10‴), 25.6 (C-11‴, C-15‴), 
130.1 (C-12‴), 128.1 (C-13‴), 31.7 (C-16‴), 22.5 (C-17‴), and 14.0 (C-18‴)]. In order to 
confirm the structure of the linoleic acid moiety, a GC-MS experiment24 was conducted (see 
Experimental Section). The attachment of the linoleic acid group to C-20 was assigned by 
the key HMBC correlations from H2-20 (δH 4.09 and 4.68) to C-1‴ (δC 174.0). The relative 
configurations of 2 were determined to be the same as those of 1 by analysis of its NOESY 
spectrum and molecular modeling, with β-orientations of H-1, H-7, H-8, H-14, H3-19, and 
H-10′ and α-orientations of H-5, H-10, H2-18, and H-9′. The structure of 2 (stelleralide E) 
was thus established as shown.
Compound 3 was isolated as a white, amorphous powder. Its HRESIMS exhibited a 
pseudomolecular peak at m/z 855.3557 [M + Na]+ (calcd for C46H56O14Na, 855.3562), 
corresponding to the molecular formula C46H56O14. In accordance with the molecular 
formula, 46 carbon signals were evident in the 13C NMR spectrum. The 1H and 13C NMR 
spectra of 3 indicated the presence of four methyl groups [δC 18.9, δH 1.80 (3H, s); δC14.5, 
δH 1.18 (3H, d, J = 6.6 Hz); δC 18.5, δH 1.22 (3H, d, J = 7.2 Hz); δC 21.1, δH 2.10 (3H, s)], a 
terminal double bond [δC 145.4, 111.9; δH 5.15 (1H, brs), 4.92 (1H, dd, J = 1.2, 1.2 Hz)], 
two hydroxymethyls [δC 66.8, δH 4.85 (1H, dd, J = 10.2, 3.0 Hz), 4.08 (1H, dd, J = 10.2, 
10.2 Hz); δC 65.8, δH 3.83 (2H, d, J = 7.2 Hz)], two benzoyl moieties (δC 166.1, 168.4, 
129.3, 130.8, 130.2 × 2, 129.6 × 2, 128.5 × 2, 128.4 × 2, 132.8, 133.6), an acetyl carbonyl 
resonance (δC 170.9), and, especially, a typical quaternary carbon resonance at δC 118.4 
(C-1′), signifying that compound 3 is a 1α-alkyldaphnane derivative.25,26 The NMR spectra 
of 3 resembled closely those of stelleralide A,7 suggesting that the two compounds have the 
same molecular skeleton and substituent groups. However, detailed comparison of their 1H 
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and 13C NMR data (Table 2) showed that an additional benzoyloxy group [δC 166.1 (Bz-
CO), 130.8 (Bz-1″), 129.6 (Bz-2″ and 6″), 128.4 (Bz-3″ and 5″), and 132.8 (Bz-4″) and δH 
8.06 (H-2″ and 6″), 7.45 (H-3″ and 5″), and 7.56 (H-4″)] is present in 3. This conclusion 
was also supported by the molecular formula of 3, which was 120 mass units greater than 
that of stelleralide A. The structure of 3 was fully determined by 2D NMR spectroscopic 
analysis. The HMBC correlations (Figure 1) from H-10′ (δH 1.22) to C-1 (δC 49.2) and C-9′ 
(δC 27.9) and from H-7′ (δH 5.34) to C-5′ (δC 19.3), C-9′ (δC 27.9), and a carbonyl group (δC 
166.1) suggested that the benzoyloxy group is attached at C-7′. The relative configuration of 
3 was established by its NOESY spectrum (Figure 1), comparison of its NMR data with 
those of stelleralide A, and molecular modeling and determined to be the same as that of 
stelleralide A with α-orientations of H-3, H-5, H-10, H-2′, H-7′, and H-10′ and β-
orientations for H-1, H-8, H-7, H-14, and H-19. Consequently, compound 3 (stelleralide F) 
was assigned as shown.
Compound 4 was assigned the molecular formula C51H48O14 based on a positive HRESIMS 
[M + Na]+ ion at m/z 917.3694. The 1H and 13C NMR spectra of 4 and 3 were similar, 
suggesting that 4 is also a 1α-alkyldaphnane derivative. Detailed comparison of the 1H 
and 13C NMR data (Table 2) of 4 with those of 3 indicated the only difference to be an 
acetyloxy group at C-18 in 3 compared with a benzoyloxy group in 4. This assignment was 
further confirmed by the HMBC correlation between H2-18 (δH 4.41 and 5.11) and the 
benzoyloxy carbonyl (δC 166.5). The relative configuration of 4 was assigned as being the 
same as that of 3 based on comparison of their NMR data, NOESY experiments, and 
molecular modeling. Therefore, the structure of 4 (stelleralide G) was determined as shown.
Stelleralide H (5) was found to have the same molecular formula, C44H54O12, as 
gnidimacrin (10), as determined by its HRESIMS. Detailed comparison of the NMR data of 
5 with those of 10 suggested that these compounds are structural analogues, differing only in 
the location of the benzoyl group. The benzoyl group was located at C-20 in 5 rather than at 
C-3 in 10 based on the HMBC correlation between H2-20 (δH 4.38) and its corresponding 
benzoyl carbonyl (δC 167.5). The configuration of 5 was elucidated by NOESY correlations 
to be the same as that of 10. Thus, the structure of 5 (stelleralide H) was established as 
shown.
Stelleralide I (6) was obtained as a white, amorphous powder, and its molecular formula was 
deduced as C35H50O9 from an HRESIMS ion at m/z 637.3349 (calcd for C35H50O9Na, 
637.3347). The 1H and 13C NMR data (Table 3) of 6 were found to be closely similar to 
those of wikstroelide B (14), a daphnanetoxin diterpene. The main difference between them 
was the presence of a hydroxy group at C-12 in 6 rather than an acetyloxy group in 14. This 
assignment was determined from the shifts in two carbon resonances: C-12 was shifted 
upfield from δc 78.2 in 14 to 77.6 in 6, and C-13 was shifted downfield from δc 83.4 in 14 to 
δc 85.0 in 6. The location of the hydroxy group at C-12 was confirmed by the HMBC 
correlations from H-12 (δH 3.94, 1H, brs) to C-9 (δC 78.5), C-11 (δC 44.9), C-13 (δC 85.0), 
C-14 (δC 80.6), and C-15 (δC 144.7). In addition, in the NOESY spectrum, H-12 correlated 
with H-18 (δH 1.23, 3H, d, J = 7.6 Hz), indicating that H-12 is α-oriented. Hence, the 
structure of compound 6 was fully established as shown.
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Stelleralide J (7) was assigned a molecular formula of C34H52O10, according to the 
HRESIMS (m/z 643.3455 [M + Na]+, calcd for C34H52O10, 643.3453). On the basis of 
its 1H and 13C NMR data (Table 3), 7 was considered to be a structural analogue containing 
18 more mass units (H2O) than wikstroelide M (16). A direct comparison of their 13C NMR 
spectra showed that the carbon resonances at δC 61.9 (C-6) and 63.6 (C-7) in 16 were shifted 
downfield to δC 76.8 and 79.1 in 7, suggesting that the 6,7-epoxide moiety in 16 is replaced 
by two hydroxy groups in 7. This deduction was confirmed from the HSQC and HMBC 
spectra, particularly HMBC correlations (Figure 1) observed between H-7 (δH 4.31) and C-5 
(δC 72.4), C-9 (δC 76.3), and C-20 (δC 67.0), as well as H-8 (δH 3.29) and C-6 (δC 76.8) 
(Figure 1). In the NOESY spectrum (Figure 1) of 7, H-8 (δH 3.29) showed significant 
correlations with H-7 (δH 4.31) and H-14 (δH 5.65), suggesting that H-7, H-8, and H-14 
have β-orientations. Correlation of H-7 (δH 4.31) and H2-20 (δH 3.77) indicated that the 
hydroxymethyl at C-6 is also β-oriented, while the hydroxy at C-6 was α-oriented (Figure 
1). A correlation was present between H-5 (δH 3.83) and H-10 (δH 3.63), but not between 
H3-18 (δH 1.06) and H-8 (δH 3.29), which indicated that H-5, H-10, and H3-18 have α-
orientations. Consequently, compound 7 (Figure 1) was elucidated as shown.
The isolated compounds (1–19) were evaluated for anti-HIV activity against NL4-3 virus 
replication in MT4 lymphocytes. Cytotoxicity [50% toxic concentration (CC50)] was also 
assessed, and the results are summarized in Table 4. The 1α-alkyldaphnane diterpenoids (3, 
4, 5, 10, and 11) exhibited the most potent anti-HIV-1 activity, with EC50 values of 0.06–1.1 
nM (SI > 10 000). The daphnanetoxin diterpenes (6, 7, 13–19) and compound 12 displayed 
lower, but still potent anti-HIV-1 effects (EC50 2.6–120 nM, SI = 100–6000). The least 
potent compounds were 1, 2, 8, and 9, which contain a 2,4-epoxide moiety and lactone ring 
(SI < 50).
Structurally, the main difference between the most potent (3–5, 10, 11) and the least potent 
(1, 2, 8, 9) compounds is in ring A. These results indicated that the nature of ring A appears 
to be responsible for the enhanced anti-HIV activity. In addition, compounds 3–5, 10, and 
11 with a cyclopentane ring A were more potent than 6, 7, and 12–19 with a cyclopentenone 
or cyclopentanone ring A, suggesting the importance of a cyclopentane ring A for optimal 
anti-HIV activity.
On the basis of their significant anti-HIV activity, compounds 3–5, 10, and 11 should be 
investigated in greater detail to develop a deeper understanding of their anti-HIV 
characteristics and potential. The new compounds likely share the same mechanisms of 
action as previously investigated daphnane- and tigliane-type diterpenes.7,10,27
EXPERIMENTAL SECTION
General Experimental Procedures
Optical rotations were measured on an Autopol V Plus instrument (Rudolph, Hackettstown, 
NJ, USA). UV spectra were recorded in MeOH using a Lambda 25 spectrophotometer 
(PerkinElmer, Wellesley, MA, USA). CD spectra were obtained on a JASCO J-715 
spectrometer. IR spectra were measured on a PE Spectrum RXI spectrophotometer 
(PerkinElmer) using KBr pellets. NMR spectroscopic data were recorded at room 
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temperature on Bruker AMX-400 MHz and AMX-600 MHz instruments in CDCl3 with 
TMS as an internal standard. Standard pulse sequences were employed for the measurement 
of 2D NMR spectra (1H–1H COSY, HSQC, HMBC, and NOESY). ESIMS analysis were 
carried out on a Dionex Ultimate 3000 UPLC instrument with an LTQ Velos Pro MS 
spectrometer (Thermo Fisher Scientific, USA). HRESIMS were acquired with a Bruker 
Daltonics APEXIII 7.0 TESLA FTMS system (Bruker Daltonics, Billerica, MA, USA). 
Analytical HPLC was carried out on an Agilent 1200 series LC instrument with a DAD 
detector (Agilent Technologies, Palo Alto, CA, USA) and a Symmetry C18 column (4.6 × 
250 mm, 5 μm). Preparative HPLC was performed on an Agilent 1100 (Agilent 
Technologies) and a YMC-Pack Pro C18 RS column (20 × 250 mm, 5 μm). Silica gel (200–
300 mesh, Qingdao Haiyang Chemical Co. Ltd., Qingdao, People’s Republic of China), 
Sephadex LH-20 (25–100 μm, Pharmacia, Germany), and RP-C18 (30–50 μm, Fuji Silysia 
Chemical Co. Ltd., Aichi, Japan) were used for column chromatography (CC). The fractions 
were monitored by TLC (HSGF 254, Yantai, People’s Republic of China), and detection 
was achieved by 10% H2SO4 in EtOH. All solvents used for CC were of analytical grade 
(Shanghai Chemical Reagents Co. Ltd., Shanghai, People’s Republic of China), and solvents 
used for HPLC were of HPLC grade. Linoleic acid was obtained from Sigma-Aldrich 
Company Ltd., Gillingham, United Kingdom.
Plant Material
The roots of S. chamaejasme (4 years old) were purchased from Baotou, Inner Mongolia, 
People’s Republic of China, in August 2011 and were authenticated by one of the authors 
(D.-F.C.). A voucher specimen (DFC-YM-SC-2011-08) is deposited in the Herbarium of 
Materia Medica, Department of Pharmacognosy, School of Pharmacy, Fudan University, 
Shanghai, People’s Republic of China.
Extraction and Isolation
The dried roots of S. chamaejasme were ground into a powder (40 kg), which was 
percolated with 95% aqueous EtOH. After removal of the solvent under vacuum, the residue 
was suspended in H2O and successively extracted with petroleum ether, EtOAc, and n-
BuOH. The petroleum ether-soluble fraction (350 g) was subjected to VLC on silica gel 
using a stepwise gradient elution of petroleum ether–Me2CO (30:1, 20:1, 10:1, 5:1, 2:1, and 
1:1) to afford five subfractions (Fr.A–Fr.E). Fr.C (40 g) was passed through a silica gel 
column eluted with petroleum ether–EtOAc (30:1 to 10:1) to give seven fractions (Fr.C1–
Fr.C7). Fr.C2 (7 g) was applied to CC on Sephadex LH-20 (n-hexane–CH2Cl2–MeOH, 
5:4:1) to obtain six fractions (Fr.C2a–Fr.C 2f). Fr.C2b (120 mg) was purified by preparative 
HPLC (10 mL/min, 50 min 85–95% MeCN–H2O gradient elution) to yield 1 (10 mg) and 2 
(8 mg). Fr.C2f (400 mg) was separated by preparative HPLC (10 mL/min, 50 min 70–95% 
MeCN–H2O gradient elution) to acquire 12 (15 mg), 13 (35 mg), and 16 (40 mg). Fr.C3 (5 
g) was chromatographed on an RP-C18 silica gel column (MeOH–H2O, 70:30 to 100:0) to 
give five fractions (Fr.C3a–Fr.C3e). Fr.C3d (1.2 g) was separated on a preparative HPLC 
column (10 mL/min, 75% MeCN–H2O isocratic elution) to obtain 3 (8 mg), 4 (5 mg), 9 (20 
mg), 10 (15 mg), and 19 (25 mg). Separation of Fr.D (30 g) by MPLC (petroleum ether–
EtOAc, 15:1 to 0:1) gave six fractions (Fr.D1–Fr.D6). Fr.D3 was purified by passage over 
Sephadex LH-20 (CHCl3–MeOH, 1:1) and then by preparative HPLC (CH3CN–H2O, 
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eluting from 65:35 to 90:10 for 40 min with a flow rate of 10 mL/min) to afford 6 (4 mg), 7 
(7 mg), 8 (25 mg), 17 (12 mg), and 15 (9 mg). Using the same purification procedures, 
Fr.D4 afforded 5 (9 mg), 11 (11 mg), 18 (7 mg), and 14 (20 mg).
Stelleralide D (1): colorless oil;  +5.3 (c 0.10, CH2Cl2); UV (CH2Cl2) λmax (log ε) 233 
(4.38) nm; CD (MeOH, nm) λmax (Δε) 208 (4.06), 228 (7.70); IR (KBr) νmax 3478, 2924, 
2854, 1799, 1718, 1648, 1452, 1396, 1270, 713 cm−1; 1H NMR (600 MHz, CDCl3) and 13C 
NMR (150 MHz, CDCl3) data, see Table 1; HRESIMS m/z 927.5235 [M + Na]+ (calcd for 
C53H76O12Na, 927.5229).
Stelleralide E (2): colorless oil;  −4.8 (c 0.10, CH2Cl2); UV (CH2Cl2) λmax (log ε) 233 
(4.16) nm; CD (MeOH, nm) λmax (Δε) 208 (4.67), 228 (7.78); IR (KBr) νmax 3459, 2923, 
2854, 2359, 2341, 1797, 1717, 1455, 1395, 1173, 717 cm−1; 1H NMR (600 MHz, CDCl3) 
and 13C NMR (150 MHz, CDCl3) data, see Table 1; HRESIMS m/z 951.5184 [M + Na]+ 
(calcd for C55H76O12Na, 951.5229).
Stelleralide F (3): white, amorphous powder;  −7.7 (c 0.10, MeOH); UV (MeOH) λmax 
(log ε) 233 (4.02) nm; CD (MeOH, nm) λmax (Δε) 215 (1.11), 236 (−1.14), 273 (0.87); IR 
(KBr) νmax 3463, 2925, 2860, 2360, 2340, 1731, 1712, 1457, 1384, 1279, 1025, 713 
cm−1; 1H NMR (600 MHz, CDCl3) and 13C NMR (150 MHz, CDCl3) data, see Table 2; 
HRESIMS m/z 855.3557 [M + Na]+ (calcd for C46H56O14Na, 855.3562).
Stelleralide G (4): white, amorphous powder;  −16.7 (c 0.10, MeOH); UV (MeOH) 
λmax (log ε) 233 (4.15) nm; CD (MeOH, nm) λmax (Δε) 215 (1.07), 237 (−7.42); IR (KBr) 
νmax 3453, 2934, 2854, 1715, 1451, 1384, 1275, 1025, 712 cm−1; 1H NMR (600 MHz, 
CDCl3) and 13C NMR (150 MHz, CDCl3) data, see Table 2; HRESIMS m/z 917.3694 [M + 
Na]+ (calcd for C51H48O14Na, 917.3719).
Stelleralide H (5): white, amorphous powder;  +4.6 (c 0.10, MeOH); UV (MeOH) λmax 
(log ε) 233 (4.31) nm; CD (MeOH, nm) λmax (Δε) 215 (4.07), 236 (−5.42); IR (KBr) νmax 
3446, 2927, 2858, 1716, 1451, 1272, 1112, 1023, 711 cm−1; 1H NMR (600 MHz, CDCl3) 
and 13C NMR (150 MHz, CDCl3) data, see Table 2; HRESIMS m/z 775.3693 [M + H]+ 
(calcd for C44H54O12 775.3688).
Stelleralide I (6): white, amorphous powder;  +21.6 (c 0.10, MeOH); UV (MeOH) λmax 
(log ε) 256 (3.98) nm; CD (MeOH, nm) λmax (Δε) 226 (−12.1), 242 (5.82); IR (KBr) νmax 
3435, 2920, 2843, 1709, 1616, 1463, 1375, 1019 cm−1; 1H NMR (400 MHz, CDCl3) 
and 13C NMR (100 MHz, CDCl3) data, see Table 3; HRESIMS m/z 637.3349 [M + Na]+ 
(calcd for C35H50O9Na, 637.3347).
Stelleralide J (7): white, amorphous powder;  +2.2 (c 0.12, MeOH); UV (MeOH) λmax 
(log ε) 256 (4.01) nm; CD (MeOH, nm) λmax (Δε) 243 (−1.69), 268 (3.08); IR (KBr) νmax 
3405, 2925, 2854, 2361, 1701, 1639, 1006 cm−1; 1H NMR (400 MHz, CDCl3) and 13C 
Yan et al. Page 8













NMR (100 MHz, CDCl3) data, see Table 3; HRESIMS m/z 643.3455 [M + Na]+ (calcd for 
C34H50O10Na, 643.3453).
Base Hydrolysis of 2 and GC-MS Analysis
Compound 2 (2 mg) in CH2C12 (2 mL) was allowed to stand at room temperature for 3 h 
with 0.05 M NaOMe in MeOH (0.5 mL). The mixture was neutralized, followed by addition 
of 10 mL of 14% BF3–MeOH, and was heated at 80 °C for 5 min. Hexane (3 mL) was 
added to the above mixture through the top of the condenser, and heating was continued for 
2 min. After dilution with a saturated NaCl solution, the organic layer was collected and 
evaporated to dryness using N2. The residue was redissolved in hexane and analyzed by GC-
MS (Shimadzu, GCMS-QP2010 Ultra) using an Inertcap column (0.25 mm × 30 m) under 
the following conditions [injector temperature, 250 °C; initial temperature, 80 °C (1 min), 
increased at 25 °C/min to 230 °C, held for 10 min; carrier gas, He operated in the splitless 
mode; injection size, 0.2 μL; MS conditions: EI voltage, 70 eV; scanned-mass range, m/z 
50–1000]. Identification of linoleic acid was carried out for 2, giving a peak at 12.23 min. 
With authentic linoleic acid, a peak was detected at 12.24 min.
Anti-HIV Assays
HIV-1 NL4-3 (multiplicity of infection = 0.001) was used to infect MT4 cells in the 
presence of various concentrations of compounds. Fresh medium, which contained 
appropriate concentrations of the compounds, was added to the culture 48 h after infection to 
maintain normal cell growth. Virus replication was analyzed on day 4 postinfection using 
p24 ELISA kits from PerkinElmer. The compound concentration that inhibited HIV-1 
replication by 50% (EC50) was calculated by using the biostatistics software CalcuSyn 
(Biosoft).
Cytotoxicity Assays
Cytotoxicity of the purified compounds toward MT4 cells was determined by using a cell 
viability kit provided by Promega. The CellTiter-Glo luminescent cell viability assay is a 
simple method of determining the viability of the cells in culture based on quantitation of 
ATP in metabolically active cells. The CellTiter-Glo reagent was added to MT4 cells that 
were cultured parallel to the antiviral assays. The cytotoxic concentration that caused the 
reduction of viable cells by 50% (CC50) was calculated from the dose–response curve using 
CalcuSyn.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
1H (600 MHz) and 13C (150 MHz) NMR Spectroscopic Data for Compounds 1 and 2 in CDCl3
position
1a 2b
δH [J in (Hz)] δC δH [J in (Hz)] δC




5 4.82 (1H, brs) 69.3 4.82 (1H, brs) 69.3
6 57.1 57.1
7 3.44 (1H, brs) 59.3 3.43 (1H, brs) 59.3
8 3.26 (1H, dd, 2.8, 1.6) 34.8 3.26 (1H, dd, 2.8, 1.6) 34.8
9 80.1 80.1
10 2.89 (1H, d, 4.0) 54.8 2.89 (1H, d, 4.2) 54.8
11 2.19 (1H, t, 6.8, 6.8) 42.8 2.19 (1H, t, 6.8, 7.2) 42.8
12 2.08 (1H, dd, 11.2, 6.8) 32.6 2.08 (1H, dd, 11.2, 6.8) 32.6
2.32 (1H, dd, 11.2, 6.8) 2.32 (1H, dd, 11.2, 6.8)
13 83.4 83.4
14 4.35 (1H, s) 80.6 4.35 (1H, s) 80.6
15 145.7 145.7
16 4.94 (1H, dd, 1.8, 1.8) 111.6 4.94 (1H, dd, 2.0, 2.0) 111.6
5.05 (1H, s) 5.03 (1H, s)
17 1.79 (3H, s) 18.8 1.79 (3H, s) 18.7
18 4.54 (1H, dd, 12.4, 6.8) 69.5 4.54 (1H, dd, 12.4, 6.8) 69.5
4.97 (1H, d, 12.5) 4.97 (1H, d, 12.5)
19 1.73 (3H, s) 19.6 1.74 (3H, s) 19.5
20 4.09, 4.68 (2H, d, 12.5) 63.9 4.09, 4.68 (2H, d, 12.5) 63.9
1′ 120.4 120.4
2′ 2.10 (1H, ddd, 12.0, 6.0, 3.0) 31.3 2.10 (1H, ddd, 12.0, 6.0, 3.0) 31.3
1.93 (1H, ddd, 12.0, 5.6, 3.0) 1.93 (1H, ddd, 12.0, 5.6, 3.0)
3′ 1.56, 1.76 (2H, m) 22.2 1.56, 1.76 (2H, m) 22.1
4′ 1.27, 1.62 (2H, m) 25.1 1.27, 1.62 (2H, m) 25.1
5′ 1.17, 1.48 (2H, m) 24.2 1.17, 1.48 (2H, m) 24.2
6′ 1.27, 1.52 (2H, m) 26.6 1.27, 1.52 (2H, m) 26.6
7′ 1.11, 1.52 (2H, m) 26.9 1.11, 1.52 (2H, m) 26.9
8′ 0.87, 2.27 (2H, m) 32.6 0.87, 2.31 (2H, m) 32.6
9′ 1.13 (1H, m) 37.8 1.13 (1H, m) 37.8
10′ 1.02 (3H, d, 6.4) 19.2 1.02 (3H,d, 6.4) 19.2
Bz-CO 166.4 166.4
Bz-1″ 130.0 130.0
Bz-2″, 6″ 8.04 (2H, dd, 8.4, 1.2) 129.5 8.04 (2H, dd, 11.2, 1.2) 129.5
Bz-3″, 5″ 7.46 (2H, dd, 8.0, 8.0) 128.5 7.45 (2H, dd, 7.6, 7.6) 128.5
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position
1a 2b
δH [J in (Hz)] δC δH [J in (Hz)] δC
Bz-4″ 7.57 (1H, dd, 7.2, 1.2) 133.2 7.57 (1H, dd, 7.6, 1.2) 133.2
a
Data for palmitic acid group: δH 2.37 (2H, t, 8.0, H-2‴), 1.62 (2H, m, H-3‴), 1.23–1.30 (24H, m, H-4‴–H-15‴), 0.86 (3H, t, 8.0, H-16‴); δC 
173.8 (C-1‴), 34.1 (C-2‴), 24.7 (C-3‴), 29.0–29.8 (C-4‴–C-13‴), 31.9 (C-14‴), 22.7 (C-15‴), 14.1 (C-16‴).
b
Data for linoleic acid group: δH 2.38 (2H, t, 8.0, H-2‴), 1.62 (2H, m, H-3‴), 1.23–1.30 (12H, m, H-4‴–H-7‴, H-16‴, and H-17‴), 2.04 (4H, m, 
H-8‴, H-14‴), 5.32 (1H, m, H-9‴), 5.37 (1H, m, H-10‴), 2.76 (4H, t, 5.2, H-11‴, H-15‴), 5.35 (1H, m, H-12‴), 5.33 (1H, m, H-13‴), and 0.88 
(3H, t, 6.8, H-18‴); δC 174.0 (C-1‴), 33.9 (C-2‴), 24.7 (C-3‴), 29.0–29.8 (C-4‴–C-7‴), 27.1 (C-8‴, C-14‴), 127.9 (C-9‴), 130.2 (C-10‴), 25.6 
(C-11‴, C-15‴), 130.1 (C-12‴), 128.1 (C-13‴), 31.7 (C-16‴), 22.5 (C-17‴), and 14.0 (C-18‴).











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Yan et al. Page 16
Table 3
1H (400 MHz) and 13C (100 MHz) NMR Spectroscopic Data for Compounds 6 and 7 in CDCl3
position
6 7
δH [J in (Hz)] δC δH [J in (Hz)] δC




5 4.25 (1H, s) 72 3.83 (1H,s) 72.4
6 60.6 76.8
7 3.55 (1H, d, 1.8) 64.3 4.31 (1H, s) 79.1
8 3.78 (1H, brs) 34.9 3.29 (1H, brs) 40.1
9 78.5 76.3
10 3.85 (1H, t, 2.8) 47.6 3.63 (1H, d, 5.0) 53.3
11 2.49 (1H, dd, 14.0, 6.8) 44.9 2.24 (1H, m) 36.5
12 3.94 (1H, brs) 77.6 2.14 (2H, m) 37.5
13 85.0 74.4
14 4.74 (1H, d, 1.8) 80.6 5.65 (1H, s) 79.8
15 144.7 145.3
16 5.14 (2H, d, 10.8) 112.9 5.06 (1H, s), 5.17 (1H, s) 114.3
17 1.89 (3H, s) 18.9 1.88 (3H, s) 18.9
18 1.23 (3H, d, 7.6) 18.6 1.06 (3H, d, 8.5) 17.6
19 1.82 (3H, s) 9.9 1.80 (3H, s) 9.8
20 3.78 (1H, d, 12.0) 65.0 3.77 (2H, d, 11.2) 67.0
3.94 (1H, d, 12.0)
1′ 116.8 168.6
2′ 5.64 (1H, d, 15.2) 139.1 5.90 (1H, d, 16.0) 118.6
3′ 6.67 (1H, dd, 15.2, 10.4) 122.7 7.35 (1H, dd, 14.0, 7.6) 146.8
4′ 5.86 (1H, dd, 14.4, 8.0) 128.6 7.35 (1H, dd, 14.0, 7.6) 128.2
5′ 5.86 (1H, dd, 14.4, 8.0) 134.9 6.21 (1H, dd, 14.0, 9.2) 146.3
6′ 2.11 (2H, dd, 14.4, 7.2) 32.7 1.29 (2H, m) 31.9
7′ 1.27 (2H, m) 29.2 1.30 (2H, m) 29.2
8′ 1.28 (2H, m) 29.2 1.30 (2H, m) 29.2
9′ 1.28 (2H, m) 29.3 1.30 (2H, m) 29.3
10′ 1.29 (2H, m) 29.3 1.30 (2H, m) 29.4
11′ 1.30 (2H, m) 29.5 1.30 (2H, m) 29.5
12′ 1.30 (2H, m) 29.5 1.30 (2H, m) 31.8
13′ 1.31 (2H, m) 31.9 1.30 (2H, m) 22.6
14′ 1.31 (2H, m) 22.6 0.89 (3H, d, 6.4) 14.1
15′ 0.90 (3H, t, 7.2) 14.1
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Table 4
Anti-HIV and Cytotoxicity Activities of Compounds 1–19a
compound
anti-HIV cytotoxicity selectivity index
EC50 (μM) CC50 (μM) CC50/EC50
1 0.59 ± 0.18 ≥11.1 ≥18
2 6.71 ± 2.46 ≥10.8 ≥1
3 0.00093 ± 0.00025 ≥12 ≥12903
4 0.00073 ± 0.00032 ≥11.2 ≥15342
5 0.00098 ± 0.00037 ≥12.9 ≥13163
6 0.12 ± 0.038 ≥16.3 ≥135
7 0.044 ± 0.015 ≥4.4 ≥100
8 0.33 ± 0.12 ≥13.8 ≥41
9 1.12 ± 0.30 ≥18.3 ≥16
10 0.00006 ± 0.00002 ≥1.29 ≥21500
11 0.0011 ± 0.0004 ≥15.7 ≥14272
12 0.048 ± 0.0180 ≥15.3 ≥318
13 0.012 ± 0.0041 ≥15.6 ≥1300
14 0.039 ± 0.0082 ≥15.3 ≥392
15 0.013 ± 0.0041 ≥16.7 ≥1284
16 0.0026 ± 0.0009 ≥14 ≥5384
17 0.059 ± 0.0150 ≥16.6 ≥281
18 0.044 ± 0.0118 ≥15.2 ≥345
19 0.047 ± 0.0148 ≥18.8 ≥400
AZT 0.032 ± 0.0082 ≥3.74 ≥116
a
The values are means ± SD (n = 3). AZT (zidovudine) was used as a positive control.
J Nat Prod. Author manuscript; available in PMC 2016 November 25.
